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Abstract
Objective. RA is associated with a 5060% increase in risk of cardiovascular (CV) death. This study aimed
to compare management of CV risk factors in RA and matched non-RA patients.
Methods. A retrospective cohort study was conducted using UK clinical practice data. Patients presenting
with an incident RA diagnosis were matched 1:4 to non-RA patients based on a propensity score for RA,
entry year, CV risk category and treatment received at index date (date of RA diagnosis). Patients tested
and treated for CV risk factors as well as those attaining CV risk factor management goals were evaluated
in both groups.
Results. Between 1987 and 2010, 24 859 RA patients were identified and matched to 87 304 non-RA
patients. At index date, groups had similar baseline characteristics. Annual blood pressure, lipids and
diabetes-related testing were similar in both groups, although CRP and ESR were higher in RA patients at
diagnosis and decreased over time. RA patients prescribed antihypertensives increased from 38.2% at
diagnosis to 45.7% at 5 years, from 14.0 to 20.6% for lipid-lowering treatments and from 5.1 to 6.4% for
antidiabetics. Similar treatment percentages were observed in non-RA patients, although slightly lower for
antihypertensives. Modest (2%) but significantly lower attainment of lipid and diabetes goals at 1 year was
observed in RA patients.
Conclusion. There were no differences between groups in the frequency of testing and treatment of CV
risk factors. Higher CV risk in RA patients seems unlikely to be driven by differences in traditional CV risk
factor management.
Key words: RA, cardiovascular, management, hypertension, dyslipidaemia, diabetes, goal, prescription, cohort.
Rheumatology key messages
. No differences were found between RA vs non-RA groups in testing or treatments for cardiovascular risk factors.
. Higher cardiovascular risk in RA is not driven by the lack of cardiovascular risk factor management.
Introduction
RA is associated with increased morbidity and mortality.
Meta-analyses of published literature have shown that RA
is associated with a 5060% increase in risk of CV death
vs the general population [13]. Despite improvements in
RA therapies, it appears that the mortality gap between
RA patients and the general population persists, and may
even be increasing [2]. Cardiovascular (CV) complications
are the primary cause for this increase in mortality and
also contribute to increased risk for CV events in RA pa-
tients compared with the non-RA population [4, 5].
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The pathogenic mechanisms underlying increased CV
risk in RA have yet to be elucidated. There is emerging
evidence to suggest that traditional CV risk factors do not
fully account for the increased likelihood of CV complica-
tions in RA, and the immune dysregulation, chronic high-
grade inflammation and metabolic disturbances found in
RA, along with RA disease activity and treatments such as
corticosteroids, contribute to CV risk in RA patients [69].
Investigators have found that several treatment regimens
for RA reduce the risk of CV events [10]. Long-term use of
DMARDs may modify atherosclerosis via beneficial effects
on endothelial function as well as inflammatory markers
[11]. With regard to biologic DMARDs (bio-DMARDs), a
meta-analysis reported that therapy with TNF-a inhibitors
was associated with a reduced risk of all CV events, myo-
cardial infarction and stroke in cohort studies [12]. A meta-
analysis of randomized controlled trials also produced a
point estimate indicating a lower risk of CV events with
TNF-a inhibitor therapies, but this was not statistically sig-
nificant [13].
Although the literature on CV risk in RA patients is ex-
tensive, there are a few limitations. The current literature
does not fully address how the traditional CV risk factors
of hypertension, lipids, weight and haemoglobin A1c
(HbA1c) are managed in RA patients in comparison to
the general population. Thus, the literature fails to inform
whether the increased risk of CV events observed in RA
patients could partly be due to worse CV risk manage-
ment. Some studies indicate a lack of screening for CV
risk factors by the rheumatologist (vs primary care pro-
viders) in RA patients and relatively low statin use
among RA patients [14, 15]. However, these studies did
not have a comparator non-RA group.
Although traditional CV risk factors may not fully explain
the excess CV risk in RA patients, it is important to under-
stand how these are managed in RA patients, especially with
the introduction of agents such as Janus kinase inhibitors
and anti-IL6 in the management of RA. These newer thera-
pies are associated with changes in lipid levels, including
increases in both low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) [16]. The objective of this analysis
was to describe the management of traditional CV risk fac-
tors, such as lipids, blood pressure and HbA1c, in RA pa-
tients in clinical practice settings and compare this
management with that of matched non-RA patients.
Methods
Study population and design
This was a retrospective cohort analysis based on the UK
clinical practice database from 1987 to 2011. The data-
base was obtained from the Clinical Practice Research
Datalink (CPRD), which contains information on resources
managed by general practitioners. It is one of the largest
computerized databases of anonymized longitudinal med-
ical records from primary care. The current CPRD data set
includes information on around 5 million currently active
patients of research standard quality from about 590 pri-
mary care practices in the UK, representing 8% of the
UK population. The CPRD population is representative of
the general UK population. Selected laboratory data are
available for a subset of patients. These mainly concern
CV and diabetes-related laboratory data. The CPRD has
been granted multiple research ethics committee approval
(05/MRE04/87) to undertake purely observational studies,
with external data linkages including Hospital Episode
Statistics (HES) and Office for National Statistics (ONS)
mortality data. The work of CPRD is also covered by
National Information Governance Board (NIGB)-Ethics and
Confidentiality Committee (ECC) approval ECC 5-05 (a)
2012. This study was approved by the Independent
Scientific Advisory Committee for Medicines and
Healthcare products Regulatory (MHRA) database research
(ISAC) under protocol number 12_079Ra.
The study population included all adult patients
(age518 years) recorded in the CPRD database with re-
cords of sufficient quality, identified through the accept-
able patient flag. The RA population was defined as all
patients presenting at least one RA read code after 1
January 1988 (index code), with no RA or juvenile RA
codes before the index code. The read codes for RA
were those that were included in group 1 or 2 of
Thomas et al. [17], and the list of codes was also validated
by clinical experts. The index date was defined as the date
of the first RA-related clinical or referral record, that is,
index code. Patients were required to have at least 12
months of follow-up before the index date.
In the CPRD database, medical diagnoses and events
were identified through read codes, and medcodes were
used for treatments. Lists of codes were constructed to
define covariates and CV risk factors, based upon most
recent values within 2 years preceding the index date. In
order to create the code list for each condition, published
lists of codes were used and supplemented by additional
searches of the medical and product browsers. The list
was then screened by an analyst in order to exclude all
non-relevant codes and then a second screening was
conducted by a person with medical qualification with ex-
pertise in read codes. Laboratory values were identified
and calculated at the index date for baseline and updated
for each subsequent year after the index date considering
the most recent value, within 2 years of the date of inter-
est. The CV risk as defined by the National Cholesterol
Education Program (NCEP, 2002) is composed of four
categories of low, medium, high and secondary preven-
tion, by summing the following risk factors: dyslipidaemia
(LDL54 mmol/l or HDL41 mmol/l), hypertension (>140/
90 mmHg), age (>45 years for males and>55 years for
females) and current smoker [18]. If patients had none of
the risk factors they were considered low risk, one risk
factor was medium risk and more than one risk factor
was high risk. Patients with diabetes, heart disease, a his-
tory of a CV event or a history of a CV procedure were
considered the target group for secondary prevention.
Matched non-RA cohort
RA patients were matched 1:4 to non-RA patients based
on their year of entry in the CPRD database, CV risk
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category (NCEP classification), treatment status at index
date and a propensity score estimating the probability of
having RA [18]. The propensity score probability was
based on a logistic regression model that included
gender, smoking, obesity, Charlson Co-morbidity Index
and family history of RA as covariates. Each RA patient
was categorized into low, medium or high CV risk at the
index date. CV risk categories and treatment status for
CV risk were calculated for all non-RA patients every
6 months. Non-RA patients were selected as potential
matches based on the CV risk category and treatment
status of the closest cut-off to the case’s index date.
Potential matches were also required to have entered
the CPRD database during the same year as the case
and to have an activity in the database within 2 months
of the case’s index date. Based on the pool of potential
matches, each RA patient was matched to a non-RA pa-
tient using the nearest neighbour match method of its RA
risk score, and consequently removed from the pool of
potential non-RA matches. This matching based on a
risk score was performed in order to select patients with
similar characteristics with the exception of RA diagnosis,
thereby reducing bias due to confounding variables. An
index date was assigned to the non-RA patient based on
the closest observation date to the RA patient’s index
date, and the match was confirmed based on the recal-
culated non-RA patient’s CV risk category at the assigned
index date. The process was repeated to match a max-
imum of four controls to each case. Standardized differ-
ences were used to compare the measured baseline
characteristics between the RA and the non-RA popula-
tions. A standardized difference of<0.1 will be considered
indicative of good balance [17].
Outcomes
Management of traditional CV risk factors was evaluated
in terms of the percentage of patients evaluated for CV
risk factors, the percentage of patients receiving treat-
ment with lipid-lowering therapies, antihypertensive thera-
pies and antidiabetic therapies at index and up to 5 years
after the index date. In addition, we evaluated the per-
centage of patients attaining blood pressure, lipids and
HbA1c goals annually up to 5 years post index date.
The goals were based on UK clinical guidelines; for
blood pressure the goal was <140/90 mmHg, for dyslipi-
daemia the goal was either an LDL cholesterol of
<2 mmol/l or total cholesterol of <4 mmol/l, and for dia-
betes the goal was HbA1c <7.5%.
Statistical analyses
Baseline characteristics between RA and matched non-
RA patients were compared using standard statistical
tests and standardized differences. Statistical analysis
involved comparing between RA and matched non-RA
patients the percentage of patients evaluated for CV risk
factors, treated for CV risk factors and attaining CV risk
factor management goals at baseline and at 5 years post
baseline. Evaluation of CV risks was based on comparing
the mean number of CV risk factor lab values (such as
HDL-C, LDL-C, Total Cholesterol, Triglyceride, Diastolic
BP, Systolic BP, CRP, ESR, HbA1c, Fast Glucose)
during each year between the RA cohort and the matched
non-RA cohort. The proportion of patients attaining blood
pressure, lipid and HbA1c goals at yearly intervals up to 5
years was compared between RA and matched non-RA
patients using 2 statistics. The analysis of attainment of
goals for blood pressure, lipids and HbA1c was based on
a last observation carried forward approach. No additional
adjustments besides imputation for missing values on la-
boratory tests using last observation carried forward were
made because the matching was successful. The analysis
was carried out using the statistical software SAS 9.2.
Graphs were plotted using Excel 2007. An a level of
0.05 was used for determination of statistical significance.
Results
Between 1987 and 2010, there were 24 859 patients with
RA who were identified in the CPRD data set with a mean
(S.D.) follow-up of 5.8 (4.4) years, representing 144 342 pa-
tient-years. Each RA patient was matched to four non-RA
patients (n = 87 304) with a mean (S.D.) follow-up of 5.7
(4.4) years. At the time of RA diagnosis, the mean (S.D.)
age for the RA cohort was 60.0 (15.1) years, and 69.2%
were females. In terms of CV risk stratification, 20% of RA
patients were categorized as secondary prevention; 30%
of the primary prevention patients were high risk, 31%
were medium risk and 19% low risk. The RA and non-
RA patients received similar baseline therapies to treat
hypertension, diabetes or dyslipidaemia (41.8 vs 40.7%).
Overall, the RA and the non-RA cohort were well matched
on the baseline age and baseline CV risks. Despite stat-
istically significant differences, the effect size is very mar-
ginal as confirmed by standardized differences close to 0.
The incremental difference in Charlson Co-morbidity
Index between RA and non-RA patients (1.1) can be ex-
plained by the Charlson Co-morbidity Index calculation
itself, because RA activity is counted as a co-morbidity
(Table 1).
The reporting of laboratory tests was similar in both
groups overall, although CRP and ESR were reported
more often in RA vs non-RA patients (33.9 vs 5.8% and
47.0 vs 12.2%, respectively, at index date). Overall, mean
blood pressure, lipid and diabetes-related laboratory test
results were stable and similar in the RA and non-RA co-
horts over time since diagnosis, although CRP and ESR
were higher in RA patients at diagnosis, decreasing over
time [average (S.D.) from 24.6 mg/l (34.9) at index date to
14.8 mg/l (25.9) at 5 years for CRP, and from 31.9 mm/h
(26.0) to 23.9 mm/h (20.9) for ESR; Table 2].
The percentage of RA patients who were prescribed
treatments for hypertension, lipid-lowering therapies and
diabetes at RA diagnosis was 38.2, 14.0 and 5.1%, re-
spectively, and these values were comparable to those
in the non-RA cohort (37.4, 14.8 and 5.8%). When com-
paring these treatment percentages between baseline
and 5 years, there was a general trend towards an
increased proportion of patients being managed for
CV risk factors in RA and non-RA patients at 5 years
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(Fig. 1). The trend was slightly higher in RA patients
(+7.5%, 95% CI 6.5, 8.6) than in non-RA patients
(+5.6%, 95% CI 5.1, 6.2) for antihypertensive use. There
was no difference in the proportion of RA patients treated
for CV risk factors compared with matched non-RA pa-
tients treated for CV risk factors over the 5 year analysis
based on the comparison of CIs (Fig. 1).
Within patients with the same risk factors at the index
date, there was no difference between RA and non-RA pa-
tients reaching goals for hypertension at 1 year (Fig. 2;
P= 0.50) although small but significant differences were
found for dyslipidaemia and diabetes (16.4 vs 18.5%, P
< 0.01 for lipid goals in RA and non-RA patients, respect-
ively, and 48.7 vs 44.3%, P < 0.01 for HbA1c goals).
Discussion
This study is the first to describe the management of CV
risk factors of RA patients in a UK clinical practice setting
and compare it with matched non-RA patients. Given that
the risk of a CV event is dependent on multiple factors, its
management is dictated by the evaluation of these risk fac-
tors and the determination of overall CV risk. Thus, it is
important to control for the baseline CV risk when evaluat-
ing the management of CV risk factors. To our knowledge,
this is the only study to have matched RA patients to non-
RA patients on baseline CV risks when evaluating the man-
agement of CV risks factors in RA patients. Given the large
number of patients included in the study and the average
follow-up of >5 years, we believe that the study population
and its management of CV risk factors is representative of
general RA patients seen in a clinical practice setting.
No meaningful differences were found between RA and
non-RA patients in terms of the frequency of CV risk factor
evaluation and treatments at baseline. However, there
were more patients managed for hypertension in the
RA-cohort vs the non-RA cohort at 5 years, and there
was a modest difference of 2% fewer patients in the RA
cohort reaching lipid goals. The evidence for hypertension
being more prevalent in RA patients is mixed, because
reports are contradictory and dependent on the definition
of hypertension used in the analysis [19]. However, results
from a recent study indicate a significantly increased pre-
valence of hypertension in RA patients vs controls and
would support our findings [20]. Our study also found
that RA patients experienced a modest absolute 2%
lower achievement in lipid goals. Studies of lipid levels
in RA are inconclusive and seem to be influenced by the
duration of RA and treatment for RA. Studies conducted
prior to RA diagnosis seem to indicate that RA patients
have low HDL vs matched controls [21]. However, other
studies have shown that RA patients have lower LDL and
total cholesterol levels and, in spite of these lower levels,
there is a paradoxical increase in CV risk [22, 23]. Our
study was not designed to compare the lipid levels be-
tween RA and non-RA patients. Given that we matched
patients on baseline CV risk factors, we could not observe
a difference in baseline lipid levels in our cohort. However,
in spite of the similarity in testing and treatment for lipid
lowering between RA and non-RA patients, we found that
attainment of lipid goals was modestly lower in RA pa-
tients. Further studies would need to be conducted to
confirm our observation and its relevance. Studying the
patterns of lipid management in RA patients is important
because new therapies introduced to manage RA have
been associated with increasing lipid levels [17].
Some of our findings are contrary to those reported in the
literature on management of CV risk factors in RA patients.
TABLE 1 Summary of baseline characteristics
Characteristics
RA patients
(n = 24859)
Non-RA patients
(n = 87304) P-values d
Number of patient-years, sum 144 342 494 938
Follow-up, mean (S.D.), years 5.8 (4.4) 5.7 (4.4) <0.0001 0.023
Agea, mean (S.D.), years 60.0 (15.1) 60.2 (15.9) 0.071 0.013
Charlson Co-morbidity Indexa, mean (S.D.) 1.4 (0.9) 0.3 (0.9) <0.0001 1.222
Females, n (%) 17 202 (69.2) 57 939 (66.4) <0.0001 0.060
Obesityb, n (%) 2880 (11.6) 9530 (10.9) 0.003 0.022
Current smokerb, n (%) 6977 (28.1) 24 122 (27.6) 0.175 0.011
Hypertensionc, n (%) 9798 (39.4) 33 382 (38.2) 0.001 0.025
Dyslipidaemiac, n (%) 6761 (27.2) 24 202 (27.7) 0.103 0.011
Diabetesc, n (%) 1742 (7.0) 7012 (8.0) <0.0001 0.038
Treatment status, n (%) 10 393 (41.8) 35 530 (40.7) 0.027 0.022
Cardiovascular risk category (NCEP algorithm), n (%) <.0001 0.000
Low 4788 (19.3) 18 169 (20.8)
Medium 7683 (30.9) 24 650 (28.2)
High 7461 (30.0) 25 322 (29.0)
Secondary prevention 4927 (19.8) 19 163 (21.9)
aAge and Charlson Co-morbidity Index were evaluated at time of index date. bObesity, current smoker: based on read codes
of the 2 years preceding the index date. cHypertension, dyslipidaemia and diabetes: based on diagnoses read codes, pre-
scriptions and tests of the 2 years preceding index date. d: standardized difference; NCEP: National Cholesterol Education
Program.
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A recent study concluded that RA patients were less likely
to be diagnosed with hypertension than patients without
RA [24]. Another study found that one-third of eligible pa-
tients lacked appropriate lipid testing despite the presence
of traditional CV risk factors [25], whereas others con-
cluded that the health-care quality in RA appears to be
suboptimal for co-morbid disease [26]. We postulate that
the difference between our findings and those from other
studies can be explained partly by the difference in meth-
odology and the settings of the studies. Firstly, as stated
previously, we controlled for baseline CV risk in our study
via matching, which was not done in the other studies.
FIG. 2 Summary of patients reaching blood pressure, lipids and haemoglobin A1c goals at 1 year post index date
aPercentage (number of patients reaching target level/number of patients followed up). bHypertension target levels: blood
pressure <140/90 mmHg. cDyslipidaemia target levels: low-density lipoprotein cholesterol <2 mmol/l or total cholesterol
<4 mmol/l. dDiabetes target levels: haemoglobin A1c <7.5%.
FIG. 1 Summary of treatments prescribed at index date
All data are percentages. aChange in percentage of patients receiving treatment (95% CI).
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Secondly, our study was conducted in the general practice
setting vs rheumatologist setting, because there is evi-
dence to support that rheumatologists identify and
manage CV risk factors significantly less frequently in RA
patients when compared with primary care providers [26].
Thirdly, it is the only study based on data from the UK,
whereas the other studies were based on US data.
Our general finding that there is no substantial differ-
ence in the evaluation, treatment and attainment of CV
risk factor goals indicates that the higher incidence of
CV events among RA patients observed in our data (CV
event incidence rate in our data set of 4.29, 95% CI 4.15,
4.44 in RA patients vs 3.11, 95% CI 3.04, 3.17 in non-RA
patients per 100 patient-years; 8.97% of RA patients and
6.97% of non-RA primary prevention patients had a CV
event over a 5 year follow-up) may not be driven by poor
management of traditional CV risk factors alone. This find-
ing indirectly supports the literature indicating that there
might be other factors contributing to increased CV
events in RA patients. Although traditional risk factors
are known to play an important role in the general popu-
lation, their relative contributions to CV risk in RA is less
clear [19]. Moreover, there is evidence that the increased
CV risk in RA patients might not be explained by trad-
itional risk factors alone [27]. The mechanisms underlying
increased CV events in RA have yet to be elucidated fully.
However, there is emerging evidence to suggest that the
immune dysregulation, chronic high-grade inflammation
and metabolic disturbances found in RA patients could
contribute to the increased CV events in RA patients
[69]. The increase in CV risk in RA patients is acknow-
ledge by the consensus guidelines for the management of
RA, which recommend the evaluation for CV risk at base-
line using a traditional CV risk algorithm, such as
Framingham Heart Study-based algorithm or the MONIC
Study-based SCORE algorithm. The Dutch guidelines rec-
ommend the application of CV risk management (CVRM)
in RA patients, because RA is considered as an independ-
ent risk factor for CV disease. A recent study showed that
CVRM guidelines performed poorly in RA patients, with an
overall increase in 10 year CV risk despite implemention of
CVRM [28]. Given that these algorithms were not de-
veloped in the RA-specific population, and to account
for the increased CV risk in RA patients vs the general
population, the EULAR guidelines recommend that the
risk calculated, using these algorithms, should be multi-
plied by a factor of 1.5.
There were several limitations to our analysis. Our study
was retrospective, implying the potential presence of
some sources of bias due to confounding factors.
However, this was partly accounted for by propensity
score matching of patients on both their RA and CV risk
profiles. Only data from a general practice setting were
available, and no data from rheumatologists were avail-
able. This could impact the identification of RA patients
into our study, which is based on read codes in groups 1
and 2 of Thomas et al. [17]. This list of codes did not in-
clude seronegative for RF RA codes and had a high sen-
sitivity (93%) but a relative low specificity (49%); thus,
there could be some false positives in our case cohort
[15]. In addition, the present analysis used the NCEP
guidelines, which were cited by the British Society of
Cardiology and in effect during the time when these pa-
tients were managed for their CV risk, that is, before 2011.
The NCEP guidelines were used to categorize the RA into
different CV risk categories, which were later used to
match patients. The results could be different if the new
ACC/AHA guidelines were used to match patients.
However, as the new guidelines were not in place when
these patients were evaluated and managed for CV risk, it
would not be appropriate to use the new guidelines in this
analysis. There were also a large number of missing
values for laboratory test data. The method of last obser-
vation carried forward was used to handle missing data
after the index date. Other imputation methods were also
investigated, such as the simple mean imputation ap-
proach, producing similar results. Finally, only prescription
data were available, which are known to differ from dis-
pensed or taken medications.
Despite limitations, the study was based on data with
both a large sample size and a good follow-up period. The
results are generalizable to the UK population and are
representative of its clinical practice, because the study
was based on the CPRD general practice database, which
covers a large proportion of the UK population.
Conclusion
There were no differences observed between RA and non-
RA patients in terms of CV risk management and testing,
although RA patients had experienced a modest 2% lower
achievement of lipid goals, which may not be clinically
meaningful. Based on this analysis, it seems that the
higher CV risk in patients with RA is unlikely to be driven
by differences in traditional CV risk factor management
alone. A focus should be placed on CV risk stratification
of RA patients and studies to determine how best to tailor
management of CV risk to the different risk groups.
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